Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?

被引：0

作者：

Davies, Rhian Sian ^{[1
]}

Nelmes, Daniel John ^{[2
]}

Butler, Rachel ^{[2
]}

Lester, Jason Francis ^{[1
]}

机构：

[1] Velindre Canc Ctr, Cardiff, S Glam, Wales

[2] Cardiff Univ, Inst Canc Genet, Cardiff, S Glam, Wales

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 08期

关键词：

EGFR mutation; exon; 19; deletion; L858R; advanced non-small cell lung cancer; NSCLC; FACTOR RECEPTOR MUTATIONS; 1ST-LINE TREATMENT; OPEN-LABEL; PHASE-III; CARBOPLATIN-PACLITAXEL; EGFR MUTATIONS; GEFITINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to EGFR tyrosine kinase inhibitors (TKIs). Trials have suggested a differential response to the second-generation EGFR TKI afatinib in favour of del19. We investigated whether this differential response is observed in clinical practice. Materials and Methods: Retrospective demographic, treatment and outcome data were collected on patients with: stage III/IV NSCLC and either del19 or L858R, receiving an EGFR TKI as first-line treatment. Results: There was no significant difference in overall survival (OS) between del19 (648 days, 95% confidence interval (CI)=461-835) and L858R (813 days, 95% CI=3871,238), (p=0.616), or in duration of therapy between del19 (365 days, 95% CI=192-538) and L858 (428 days, 95% CI=263-593), (p=0.928). Conclusion: Patients with exon del19 did not have a significantly longer OS with first-generation TKIs.

引用

页码：4267 / 4271

页数：5

共 15 条

[1] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].

Fukuoka, Masahiro ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Sunpaweravong, Patrapim ;

Leong, Swan-Swan ;

Sriuranpong, Virote ;

Chao, Tsu-Yi ;

Nakagawa, Kazuhiko ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Duffield, Emma L. ;

Rukazenkov, Yuri ;

Speake, Georgina ;

Jiang, Haiyi ;

Armour, Alison A. ;

To, Ka-Fai ;

Yang, James Chih-Hsin ;

Mok, Tony S. K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874

[2] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].

Inoue, A. ;

Kobayashi, K. ;

Maemondo, M. ;

Sugawara, S. ;

Oizumi, S. ;

Isobe, H. ;

Gemma, A. ;

Harada, M. ;

Yoshizawa, H. ;

Kinoshita, I. ;

Fujita, Y. ;

Okinaga, S. ;

Hirano, H. ;

Yoshimori, K. ;

Harada, T. ;

Saijo, Y. ;

Hagiwara, K. ;

Morita, S. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59

[3] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[4] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[5] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[6] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[7] Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. [J].

Rosell, Rafael ;

Moran, Teresa ;

Queralt, Cristina ;

Porta, Rut ;

Cardenal, Felipe ;

Camps, Carlos ;

Majem, Margarita ;

Lopez-Vivanco, Guillermo ;

Isla, Dolores ;

Provencio, Mariano ;

Insa, Amelia ;

Massuti, Bartomeu ;

Luis Gonzalez-Larriba, Jose ;

Paz-Ares, Luis ;

Bover, Isabel ;

Garcia-Campelo, Rosario ;

Angel Moreno, Miguel ;

Catot, Silvia ;

Rolfo, Christian ;

Reguart, Noemi ;

Palmero, Ramon ;

Miguel Sanchez, Jose ;

Bastus, Roman ;

Mayo, Clara ;

Bertran-Alamillo, Jordi ;

Angel Molina, Miguel ;

Javier Sanchez, Jose ;

Taron, Miquel .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :958-U38

[8] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[9] Epidermal growth factor receptor mutations in lung cancer [J].

Sharma, Sreenath V. ;

Bell, Daphne W. ;

Settleman, Jeffrey ;

Haber, Daniel A. .

NATURE REVIEWS CANCER, 2007, 7 (03) :169-181

[10] The cancer genome [J].

Stratton, Michael R. ;

Campbell, Peter J. ;

Futreal, P. Andrew .

NATURE, 2009, 458 (7239) :719-724

← 1 2 →